Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials

Sarah R. Vreijling, Cherise R. Chin Fatt, Leanne M. Williams, Alan F. Schatzberg, Tim Usherwood, Charles B. Nemeroff, A. John Rush, Rudolf Uher, Katherine J. Aitchison, Ole Köhler-Forsberg, Marcella Rietschel, Madhukar H. Trivedi, Manish K. Jha, Brenda W.J.H. Penninx, Aartjan T.F. Beekman, Rick Jansen, Femke Lamers

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Background Profiling patients on a proposed 'immunometabolic depression' (IMD) dimension, described as a cluster of atypical depressive symptoms related to energy regulation and immunometabolic dysregulations, may optimise personalised treatment. Aims To test the hypothesis that baseline IMD features predict poorer treatment outcomes with antidepressants. Method Data on 2551 individuals with depression across the iSPOT-D (n = 967), CO-MED (n = 665), GENDEP (n = 773) and EMBARC (n = 146) clinical trials were used. Predictors included baseline severity of atypical energy-related symptoms (AES), body mass index (BMI) and C-reactive protein levels (CRP, three trials only) separately and aggregated into an IMD index. Mixed models on the primary outcome (change in depressive symptom severity) and logistic regressions on secondary outcomes (response and remission) were conducted for the individual trial data-sets and pooled using random-effects meta-analyses. Results Although AES severity and BMI did not predict changes in depressive symptom severity, higher baseline CRP predicted smaller reductions in depressive symptoms (n = 376, βpooled = 0.06, P = 0.049, 95% CI 0.0001-0.12, I2 = 3.61%); this was also found for an IMD index combining these features (n = 372, βpooled = 0.12, s.e. = 0.12, P = 0.031, 95% CI 0.01-0.22, I2 = 23.91%), with a higher - but still small - effect size compared with CRP. Confining analyses to selective serotonin reuptake inhibitor users indicated larger effects of CRP (βpooled = 0.16) and the IMD index (βpooled = 0.20). Baseline IMD features, both separately and combined, did not predict response or remission. Conclusions Depressive symptoms of people with more IMD features improved less when treated with antidepressants. However, clinical relevance is limited owing to small effect sizes in inconsistent associations. Whether these patients would benefit more from treatments targeting immunometabolic pathways remains to be investigated.

Original languageEnglish
Pages (from-to)89-97
Number of pages9
JournalBritish Journal of Psychiatry
Volume224
Issue number3
DOIs
StatePublished - 22 Mar 2024
Externally publishedYes

Keywords

  • Antidepressants
  • depressive disorders
  • inflammation
  • profiling
  • treatment

Fingerprint

Dive into the research topics of 'Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials'. Together they form a unique fingerprint.

Cite this